A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia.

Aged Antineoplastic Combined Chemotherapy Protocols / adverse effects Humans Hydrazines / adverse effects Leukemia, Myeloid, Acute Physicians Triazoles / adverse effects
AML Selinexor refractory relapsed

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
12 2021
Historique:
pubmed: 30 7 2021
medline: 15 4 2022
entrez: 29 7 2021
Statut: ppublish

Résumé

Selinexor, a selective inhibitor of nuclear export, has demonstrated promising activity in patients with acute myeloid leukemia (AML). This randomized, phase II study evaluated selinexor 60 mg twice weekly (

Identifiants

DOI: 10.1080/10428194.2021.1950706 PMID: 34323164
pubmed: 34323164
doi: 10.1080/10428194.2021.1950706
doi:

Substances chimiques

Hydrazines 0
Triazoles 0
selinexor 31TZ62FO8F

Banques de données

ClinicalTrials.gov
['NCT02088541']

Types de publication

Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3192-3203

Auteurs

Kendra Sweet (K)

Moffitt Cancer Center, Tampa, FL, USA.

Bhavana Bhatnagar (B)

Ohio State University, Columbus, OH, USA.

Hartmut Döhner (H)

University of Ulm, Ulm, Germany.

Will Donnellan (W)

Sarah Cannon Cancer Center, Nashville, TN, USA.

Olga Frankfurt (O)

Northwestern University, Chicago, IL, USA.

Michael Heuser (M)

Hannover Medical School, Hannover, Germany.

Vamsi Kota (V)

Emory University, Atlanta, GA, USA.

Hongtao Liu (H)

University of Chicago, Chicago, IL, USA.

Emmanuel Raffoux (E)

Hôpital Saint-Louis, Paris, France.

Gail J Roboz (GJ)

Weill Cornell Medicine, New York, NY, USA.

Christoph Röllig (C)

Dresden University of Technology, Dresden, Germany.

Margaret M Showel (MM)

Johns Hopkins University, Baltimore, MD, USA.

Stephen A Strickland (SA)

Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.

Susana Vives (S)

ICO Badalona-Hospital Germans Trias i Pujol, Badalona, Spain.

Shijie Tang (S)

Karyopharm Therapeutics, Newton, MA, USA.

Thaddeus J Unger (TJ)

Karyopharm Therapeutics, Newton, MA, USA.

Anita Joshi (A)

Karyopharm Therapeutics, Newton, MA, USA.

Yao Shen (Y)

DarwinHealth Inc, New York, NY, USA.

Mariano J Alvarez (MJ)

DarwinHealth Inc, New York, NY, USA.
Columbia University, New York, NY, USA.

Andrea Califano (A)

Columbia University, New York, NY, USA.

Marsha Crochiere (M)

Karyopharm Therapeutics, Newton, MA, USA.

Yosef Landesman (Y)

Karyopharm Therapeutics, Newton, MA, USA.

Michael Kauffman (M)

Karyopharm Therapeutics, Newton, MA, USA.

Jatin Shah (J)

Karyopharm Therapeutics, Newton, MA, USA.

Sharon Shacham (S)

Karyopharm Therapeutics, Newton, MA, USA.

Michael R Savona (MR)

Vanderbilt University, Nashville, TN, USA.

Pau Montesinos (P)

Departamento de Hematologia, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
ORCID: 0000-0002-3275-5593

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › A 2:1 randomized, open-label, phase II study...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › A 2:1 randomized, open-label, phase II study...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A 2:1 randomized, open-label, phase II study...
questionsmedicales.fr › Composés chimiques organiques › Hydrazines › A 2:1 randomized, open-label, phase II study...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › A 2:1 randomized, open-label, phase II study...
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Personnel de santé › Médecins › A 2:1 randomized, open-label, phase II study...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Triazoles › A 2:1 randomized, open-label, phase II study...